Third-Generation EGFR Tyrosine Kinase Inhibitor in Lung Cancer
Posted: Thursday, July 30, 2020
According to findings from the single-arm phase II APOLLO study, presented as part of the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting I (Abstract CT190), almonertinib may help slow disease progression for patients with EGFR T790M–positive non–small cell lung cancer (NSCLC). Almonertinib is a third-generation EGFR tyrosine kinase inhibitor.
“Almonertinib demonstrated progression-free survival benefit in EGFR T790M–positive [patients with NSCLC] who had progressed after previous EGFR-[tyrosine kinase inhibitor] treatment, especially showed clinically meaningful efficacy against [central nervous system] metastases, and the safety profile was consistent with that reported previously,” concluded Shun Lu, MD, of Shanghai Chest Hospital, and colleagues.
The study included 244 patients enrolled between May 2018 and October 2018 in 36 sites across China (n = 189) and Taiwan (n = 55). Patients received 11 mg of oral almonertinib each day until disease progression. At data cutoff on August 1, 2019, the overall response rate was 68.9%, with 168 patients achieving confirmed partial responses. The rate of disease control was 93.4%, with median progression-free survival of 12.3 months and median duration of response of 12.4 months.
Among the 88 patients with central nervous system metastases identified on baseline brain scans, “23 had at least one intracranial measurable target lesion.” Almonertinib was found to be clinically effective in this population as well, with an overall response rate of 60.9%. The median disease control rate was 91.3%, and median progression-free survival was 10.8 months.
Overall, the most common grade 3 or 4 adverse events associated with almonertinib were increased blood creatine phosphokinase (7%) and pulmonary embolism (2.5%). The safety profile was consistent with previous findings.
Disclosure: For full disclosures of the study authors, visit abstractsonline.com.
